%0 Journal Article %A Daniela Frasca %A Lisa Reidy %A Carolyn Cray %A Alain Diaz %A Maria Romero %A Kristin Kahl %A Bonnie B. Blomberg %T Effects of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients %D 2020 %R 10.1101/2020.12.18.20248483 %J medRxiv %P 2020.12.18.20248483 %X SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus-2), cause of COVID-19 (Coronavirus Disease of 2019), represents a significant risk to people living with pre-existing conditions associated with exacerbated inflammatory responses and consequent dysfunctional immunity. In this paper, we have evaluated the effects of obesity, a condition associated with chronic systemic inflammation, on the secretion of SARS-CoV-2-specific IgG antibodies in the blood of COVID-19 patients. Results have shown that SARS-CoV-2 IgG antibodies are negatively associated with Body Mass Index (BMI) in COVID-19 obese patients, as expected based on the known effects of obesity on humoral immunity. Antibodies in COVID-19 obese patients are also negatively associated with serum levels of pro-inflammatory and metabolic markers of inflammaging and pulmonary inflammation, such as SAA (serum amyloid A protein), CRP (C-reactive protein) and ferritin, but positively associated with NEFA (nonesterified fatty acids). These results altogether could help to identify an inflammatory signature with strong predictive value for immune dysfunction that could be targeted to improve humoral immunity in individuals with obesity as well as with other chronic inflammatory conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by NIH awards AG32576 (DF/BBB), AG059719 (DF), and by the University of Miami Department of Pathology & Laboratory Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved and reviewed by the Institutional Review Board (IRB, protocols #20200504) at the University of Miami, which reviews all human research conducted under the auspices of the University of Miami.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in this study are available upon request to the corresponding author. %U https://www.medrxiv.org/content/medrxiv/early/2020/12/20/2020.12.18.20248483.full.pdf